^
    CANCER:

    Cholangiocarcinoma





    Show legend
    Group by Gene:
    Include preclinical:

    futibatinib
    pemigatinib
    infigratinib
    FGFR inhibitor
    		0
    FGFR inhibitor
    KIN-3248
    Debio 1347
    ARQ 087
    ICP-192
    ABSK091
    TT-00420
    ponatinib
    		1
    Multi-tyrosine kinase inhibitor
    cabozantinib tablet
    anlotinib
    pazopanib
    regorafenib
    gemcitabine
    		2
    DNA synthesis inhibitor
    cisplatin + gemcitabine
    FF-10502
    3
    PD-L1 inhibitor
    durvalumab
    PD-L1 inhibitor
    PD1 inhibitor
    		4
    PD1 inhibitor
    pembrolizumab
    sintilimab
    PDR001
    5
    PARP inhibitor
    olaparib
    6
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    7
    IDH1 inhibitor
    ivosidenib
    8
    c-MET inhibitor
    c-MET inhibitor
    capmatinib
    9
    FGFR2 inhibitor
    FGFR2 inhibitor
    RLY-4008
    10
    STAB1 inhibitor
    bexmarilimab
    11
    RET inhibitor
    pralsetinib
    12
    HER2 exon 20 mutation inhibitor
    BI 1810631
    13
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    14
    EphB4 inhibitor
    sEphB4-HSA
    15
    FGFR inhibitor, Tyrosine kinase inhibitor
    infigratinib + PD173074
    16
    HER2 inhibitor, HER2 dimerization inhibitor
    pertuzumab / trastuzumab / hyaluronidase-zzxf
    trastuzumab + pertuzumab
    17
    HER2 inhibitor
    HER2 inhibitor
    trastuzumab
    18
    ALK inhibitor
    crizotinib
    19
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    20
    KRAS G12C inhibitor
    adagrasib
    21
    HER2 inhibitor, HER3 inhibitor
    MCLA-128
    22
    MDM2-p53 antagonist
    BI 907828
    23
    AMPK activator
    metformin
    24
    PD1 inhibitor, PARP inhibitor
    pembrolizumab + olaparib
    25
    ERK2 inhibitor, ERK1 inhibitor
    LTT462
    26
    EGFR inhibitor
    erlotinib
    27
    MEK inhibitor, Multi-tyrosine kinase inhibitor
    trametinib + pazopanib
    28
    mTOR inhibitor
    everolimus
    29
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    30
    MEK inhibitor
    trametinib
    31
    DNA synthesis inhibitor, Bcl2 inhibitor, Tubulin inhibitor
    gemcitabine + albumin-bound paclitaxel
    32
    PD-L1 inhibitor, PD1 inhibitor
    PD1 inhibitor + PD-L1 inhibitor
    33
    Immunotherapy
    Immunotherapy
    34
    BRAF inhibitor
    BRAF inhibitor
    35
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    36
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    37
    HER2 inhibitor, EGFR inhibitor
    trastuzumab + lapatinib
    lapatinib
    38
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    39
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib + toripalimab-tpzi
    40
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    41
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ado-trastuzumab emtansine
    42
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, HER2 inhibitor, HER4 inhibitor, PD1 inhibitor, EGFR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib + pyrotinib
    43
    FGFR inhibitor, PD1 inhibitor
    pembrolizumab + pemigatinib
    44
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    neratinib
    		45
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    ASLAN001
    afatinib
    46
    FGFR2 inhibitor, FGFR1 inhibitor, FGFR3 inhibitor
    HMPL-453
    TT-00434
    47
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    48
    ROS1 inhibitor, Trk inhibitor, ALK inhibitor, Multi-tyrosine kinase inhibitor
    repotrectinib
    49
    GCN2 activator
    NXP800
    50
    Tubulin polymerization promoter, DNA synthesis inhibitor
    cisplatin + carboplatin
    51
    B7-H4-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    AZD8205
    52
    Tyrosine kinase inhibitor
    PD173074
    53
    CDK7 inhibitor
    SY‑079
    54
    HER2 inhibitor, HER4 inhibitor, PI3K inhibitor, EGFR inhibitor
    AN2025 + ASLAN001
    55
    FGFR inhibitor, VEGFR inhibitor, PDGFR inhibitor, pan-TRK inhibitor
    TKI258
    56
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor
    bosutinib
    57
    Src kinase inhibitor, FAK inhibitor
    AZD0530
    58
    FGFR inhibitor, AXL inhibitor
    pemigatinib + TP-0903
    pemigatinib + BGB324
    59
    AXL inhibitor
    TP-0903
    BGB324
    60
    IDH2 inhibitor, IDH1 inhibitor
    NMS-173
    61
    GPC-1-targeted antibody-drug conjugate
    anti-GPC-1 ADC
    No biomarker
    FGFR2 fusion
    FGFR2 mutation
    FGFR2 rearrangement
    FGFR2 E565A
    FGFR2 N549D
    FGFR2 V564L
    FGFR2 N549K
    FGFR2 translocation
    FGFR2 V564I
    FGFR2 V564F
    FGFR2 E565K
    FGFR2 E565G
    FGFR2 N549H
    FGFR2 amplification
    FGFR2 F276C
    FGFR2 C382R
    FGFR2 M540_I541insMM
    FGFR2 N549T
    FGFR2 Y376C
    FGFR2 overexpression
    HER-2 amplification
    HER-2 expression
    HER-2 overexpression
    HER-2 mutation
    HER-2 positive
    IDH1 mutation
    BRAF D594G
    BRAF V600E
    IDH1 R132
    BRAF mutation
    BRAF wild-type
    IDH1 R132C
    BRAF V600
    IDH1 R132V
    FGFR2-BICC1 fusion
    MET amplification
    PD-L1 expression
    MET elevation
    PD-L1 overexpression
    MSI-H/dMMR + PD-L1 expression
    ARID1A mutation
    NTRK2 fusion
    FGFR2-TACC3 fusion
    FGFR mutation
    BAP1 mutation + FGFR2 rearrangement
    BAP1 mutation + FGFR2 fusion
    IDH1 mutation + FGFR2 fusion
    IDH1 mutation + FGFR2 rearrangement
    BRCA2 mutation
    FGFR3 mutation
    EFNB2 positive
    EFNB2 negative
    KRAS G12C
    BRCA2 rearrangement
    KRAS mutation
    FGFR fusion
    TP53 mutation + FGFR2 fusion
    FGFR3 fusion
    TP53 mutation + FGFR2 rearrangement
    KRAS G12D
    FGFR expression
    EHBP1‐MET fusion
    MSI-H/dMMR
    RET fusion
    BRCA1 mutation
    NTRK3 fusion
    NTRK1 fusion
    IDH2 mutation
    NRG1 fusion
    MDM2 amplification
    FGFR1 fusion
    POLE mutation
    TIMP1-L
    PBRM1 mutation + FGFR2 fusion
    PIK3CA mutation + FGFR2 rearrangement
    PIK3CB mutation + FGFR2 rearrangement
    PIK3R1 mutation + FGFR2 rearrangement
    FGFR2-AHCYL1 fusion
    BAP1 mutation
    MALT1 expression
    DCK positive
    FGFR2-KIAA1217 fusion
    LMNA-NTRK1 fusion + NTRK1 G595R
    IFNG-L
    TNFA-L
    PBRM1 mutation
    PD-1 overexpression
    FGFR2-ARHGAP24 fusion
    MSI-H/dMMR + PD-1 expression + CD8 positive
    VHL mutation
    BRCA1 mutation + PD-L1 expression
    FGFR2-OGA fusion
    ERRFI1 deletion
    NCOA4-RET fusion
    BAP1 581-17_585del22 + RAD21 amplification
    FRS2 amplification
    FGFR2-POC1B fusion
    FDFT1 rearrangement + FGFR2 rearrangement
    PIK3CA mutation
    BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion
    CAPZA2-MET fusion + MET amplification
    IDH2 R172K
    FGFR1 overexpression
    DDR
    IDH1 R132C + PIK3CA E545K + IDH2 R172K
    SRC T341I
    ATP1B1-NRG1 fusion
    FGFR2-SORBS1 fusion
    FGFR2-ZMYM4 fusion
    FGFR2-NRAP fusion
    FGFR2-OPTN fusion
    VTCN1 underexpression
    FGFR2-CLIP1 fusion
    GPC1 overexpression
    TP53 mutation
    FGFR3-TACC3 fusion
    FGFR2-AFF4 fusion
    PTEN mutation + MSI-H/dMMR
    MSI-H/dMMR + TMB-L
    AR overexpression
    NRAS Q61
    CDK7 overexpression
    EGFR overexpression + HER-2 overexpression
    YAP1 positive
    FGFR2-CCDC6 fusion